SCHEMBL3030012

SCHEMBL3030012

CC(=O)c1cc(/C=C/c2ccc(O)cc2)cc(C(C)=O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 4/20 0.55
▸ MAPT P10636 4/20 0.55
▸ CA5A P35218 4/20 0.55
▸ MAOB P27338 4/20 0.55
▸ KDM4E B2RXH2 3/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ KMT2A Q03164 3/20 0.55
▸ CYP2C9 P11712 3/20 0.55
▸ CA12 O43570 3/20 0.55
▸ CA1 P00915 3/20 0.55
▸ CA2 P00918 3/20 0.55
▸ CA3 P07451 3/20 0.55
▸ CA4 P22748 3/20 0.55
▸ CA6 P23280 3/20 0.55
▸ CA7 P43166 3/20 0.55
▸ CA9 Q16790 3/20 0.55
▸ CA14 Q9ULX7 3/20 0.55
▸ CA5B Q9Y2D0 3/20 0.55
▸ CYP1A1 P04798 3/20 0.55
▸ ALOX5 P09917 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3030016 1.00 TTR (0.55) TTRMAPTCA5AMAOBKDM4E
SCHEMBL3641850 0.96 HSD17B1 (0.55) TTRMAPTCA5AMAOBKDM4E
SCHEMBL3028357 0.88 PTGS1 (0.47) TTRMAPTCA5AMAOBKDM4E
SCHEMBL3028363 0.88 PTGS1 (0.47) TTRMAPTCA5AMAOBKDM4E
SCHEMBL18860735 0.81 PTGS1 (0.61) TTRMAPTCA5AMAOBKDM4E
SCHEMBL18860733 0.81 PTGS1 (0.61) TTRMAPTCA5AMAOBKDM4E
Resveratrol SCHEMBL29128880 0.80 PTGS1 (0.79) TTRMAPTCA5AMAOBKDM4E
SCHEMBL16687974 0.79 MAOB (0.49) TTRMAPTMAOBKDM4EMEN1
Resveratrol SCHEMBL21225662 0.78 PTGS2 (0.76) TTRMAPTCA5AMAOBKDM4E
Resveratrol SCHEMBL28375834 0.78 PTGS1 (0.76) TTRMAPTCA5AMAOBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2679243-B1 Co-precipitate of one or more stilbene polyphenols in lamellar anionic solids, it's applications and related preparation method FIORETTI BERNARD (IT) 2017-05-24 — — EP claimed
US-8912234-B2 Composition containing resveratrol and/or derivatives thereof and plant oil, process for producing said composition, nutraceutical and/or pharmaceutical product, and method for enhancing the potential of resveratrol UNIAO Brasileria de Educacao e Assistencia—Mantenedora da PUCRS (BR) 2014-12-16 — — US claimed
US-20130040920-A1 COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL UNIAO Brasileira de Educacao e Assistencia- Matenedora da PUCRS (BR) 2013-02-14 — — US claimed
US-20100204179-A1 Resveratrol complex and process for the preperation UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTÊNCIA - MANTENEDORA DA PUCRS (BR) 2010-08-12 — — US claimed
EP-2178525-A1 RESVERATROL COMPLEX AND PROCESS FOR THE PREPERATION União Brasileira De Educação E Assistência - Mantenedora Da Pucrs (BR) 2010-04-28 — — EP claimed
WO-2009012551-A1 RESVERATROL COMPLEX AND PROCESS FOR THE PREPERATION UNIÄO BRASILEIRA DE EDUCAÇAO E ASSITENCIA-MANTENEDORA DA PUCRS (BR) 2009-01-29 — — WO claimed
US-20230061229-A1 SMART WOUND DRESSINGS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2023-03-02 — — US disclosed
EP-4084834-A1 SMART WOUND DRESSINGS Inteligels Ltd. (IL) 2022-11-09 — — EP disclosed
WO-2021137242-A1 SMART WOUND DRESSINGS INTELIGELS LTD. (IL) 2021-07-08 — — WO disclosed
EP-2679243-B1 Co-precipitate of one or more stilbene polyphenols in lamellar anionic solids, it's applications and related preparation method FIORETTI BERNARD (IT) 2017-05-24 — — EP disclosed
US-8912234-B2 Composition containing resveratrol and/or derivatives thereof and plant oil, process for producing said composition, nutraceutical and/or pharmaceutical product, and method for enhancing the potential of resveratrol UNIAO Brasileria de Educacao e Assistencia—Mantenedora da PUCRS (BR) 2014-12-16 — — US disclosed
US-8476248-B2 Process for the preparation of a water-soluble complex having resveratrol compounds; products comprising said complex; and uses thereof Uniao Brasileira de Educacao e Assistencia—Mantenedora da PUCRS (BR) 2013-07-02 — — US disclosed
US-20130040920-A1 COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL UNIAO Brasileira de Educacao e Assistencia- Matenedora da PUCRS (BR) 2013-02-14 — — US disclosed
US-20100204179-A1 Resveratrol complex and process for the preperation UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTÊNCIA - MANTENEDORA DA PUCRS (BR) 2010-08-12 — — US disclosed
EP-2178525-A1 RESVERATROL COMPLEX AND PROCESS FOR THE PREPERATION União Brasileira De Educação E Assistência - Mantenedora Da Pucrs (BR) 2010-04-28 — — EP disclosed
WO-2009012551-A1 RESVERATROL COMPLEX AND PROCESS FOR THE PREPERATION UNIÄO BRASILEIRA DE EDUCAÇAO E ASSITENCIA-MANTENEDORA DA PUCRS (BR) 2009-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040920-A1 COMPOSITION CONTAINING RESVERATROL AND/OR DERIVATIVES THEREOF AND PLANT OIL, PROCESS FOR PRODUCING SAID COMPOSITION, NUTRACEUTICAL AND/OR PHARMACEUTICAL PRODUCT, AND METHOD FOR ENHANCING THE POTENTIAL OF RESVERATROL GPR119, MAVS, SIRT1 TTR 1952/4885MAPT 1683/4885CA5A 2035/4885
US-20100204179-A1 Resveratrol complex and process for the preperation SI, GPR119, GYS1 TTR 313/4885MAPT 1054/4885CA5A 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback